Zoetis Inc. (NYSE:ZTS) Shares Acquired by Avidian Wealth Enterprises LLC

Avidian Wealth Enterprises LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 53.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,564 shares of the company’s stock after purchasing an additional 1,242 shares during the period. Avidian Wealth Enterprises LLC’s holdings in Zoetis were worth $581,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ZTS. Community Financial Services Group LLC raised its holdings in Zoetis by 3.7% in the fourth quarter. Community Financial Services Group LLC now owns 33,693 shares of the company’s stock valued at $5,490,000 after acquiring an additional 1,212 shares in the last quarter. TCV Trust & Wealth Management Inc. raised its holdings in Zoetis by 1.6% in the fourth quarter. TCV Trust & Wealth Management Inc. now owns 78,401 shares of the company’s stock valued at $12,774,000 after acquiring an additional 1,217 shares in the last quarter. Portfolio Design Labs LLC raised its holdings in Zoetis by 19.4% in the fourth quarter. Portfolio Design Labs LLC now owns 2,799 shares of the company’s stock valued at $456,000 after acquiring an additional 454 shares in the last quarter. Atlantic Edge Private Wealth Management LLC raised its holdings in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Finally, Wealthcare Capital Partners LLC acquired a new stake in Zoetis in the fourth quarter valued at $308,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $165.28 on Friday. The firm has a 50-day moving average price of $169.08 and a 200 day moving average price of $179.08. The firm has a market capitalization of $74.57 billion, a PE ratio of 31.07, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ZTS shares. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Piper Sandler dropped their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $214.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.